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VLCC to market CMFRI’s anti-obesity product 
KOCHI: The Central Marine Fisheries Research Institute (CMFRI) has given VLCC the 
exclusive licence to use its recently-developed anti-obesity nutraceutical product 
CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) for commercial 
production and marketing. 
CMFRI director A Gopalakrishnan signed a licence agreement with VLCC Group director 
Sandeep Ahuja and executive vice-president (research and development) A H Zaidi. After 
years of intensive research, the CMFRI developed the nutraceutical product using natural 
marine bio-active ingredients from select seaweeds. The product was found effective in 
combating obesity and dyslipidemia, an abnormal amount of lipids in the blood.  
Gopalakrishnan said the product provided a unique blend of 100 per cent natural marine 
bio-active ingredients from selected seaweeds with an eco-friendly „green technology‟, 
which is under patent. 
“Detailed pre-clinical trials have established the product is devoid of any side-effects even 
in long-term oral administration of tablets. The product is prepared from seaweeds which 
are known for their medicinal properties and are commonly available in the Indian coast,” 
he said. 
“CadalminTM ACe is the fourth in the series of the nutraceutical products developed by 
CMFRI from seaweeds,” he said. 
The CMFRI, which has already developed nutraceuticals for diabetes and arthritis, is in the 
process of developing more health products and nutraceuticals from seaweeds found in 
abundance in the country‟s coastal waters,” Gopalakrishnan said.  
  
   
                                              
